Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03224598 · ClinicalTrials.gov registry record · Phase 2
A Study of A-101 Topical Solution in Subjects With Dermatosis Papulosa Nigra
A Phase 2 study of Dermatosis Papulosa Nigra, sponsored by Aclaris Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
- 2
- Study locations
NCT03224598: Completed Phase 2 study of Dermatosis Papulosa Nigra, sponsored by Aclaris Therapeutics.
NCT03224598 is a Phase 2 study of Dermatosis Papulosa Nigra that has completed, run by Aclaris Therapeutics. The registered enrollment target is 39 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (71% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03224598, a Phase 2 study of Dermatosis Papulosa Nigra, has completed, sponsored by Aclaris Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
- 2
- Study locations
Study Summary
Evaluate the safety and efficacy of hydrogen peroxide, A-101 Solution 40% for the treatment of DPN lesions on subjects with a Fitzpatrick Skin Type of 5 or 6.
Primary Outcome
Efficacy endpoints will include summary statistics (frequency distributions, proportions, means, medians and standard deviations, as appropriate) by visit for the following parameters: Physician's DPN Lesion Assessment scale results per treated lesion, subject responders defined by Physician's DPN Lesion Assessment scale outcome, and changes from baseline treated lesion diameter Physician's DPN Lesion Assessment Grade Descriptor 0 Clear: no visible DPN lesion; 1. Near Clear: a slightly visible
Conditions Studied
Interventions
- DRUG A-101 Topical Solution 40%
Study Locations (2)
District of Columbia
- Aclaris Investigational Site - Washington D.C.
New York
- Aclaris Investigational Site - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2017-06-26 |
| Est. Completion | 2019-01-08 |
| Phase | Phase 2 |
What the finished NCT03224598 record still lists
NCT03224598 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (71% lower).
The record links to 1 condition, with Dermatosis Papulosa Nigra appearing as the primary indexed condition, and to 1 intervention - of which A-101 Topical Solution 40% is the first listed.
NCT03224598 reports a single indexed study location in District of Columbia, New York.
Frequently Asked Questions
What is clinical trial NCT03224598 about?
NCT03224598 is a clinical study titled "A Study of A-101 Topical Solution in Subjects With Dermatosis Papulosa Nigra". Evaluate the safety and efficacy of hydrogen peroxide, A-101 Solution 40% for the treatment of DPN lesions on subjects with a Fitzpatrick Skin Type of 5 or 6.
What is the current status of trial NCT03224598?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2017-06-26. Estimated completion is 2019-01-08.
What conditions does trial NCT03224598 study?
This clinical trial studies the following conditions: Dermatosis Papulosa Nigra.
What interventions are being tested in trial NCT03224598?
The interventions under investigation include: A-101 Topical Solution 40% (DRUG).
Who is sponsoring clinical trial NCT03224598?
This trial is sponsored by Aclaris Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03224598 being conducted?
This trial has 2 study locations across District of Columbia, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dermatosis Papulosa Nigra
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03224598's enrollment target sits among peer trials
39 1459th of 2000 higher than 534 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI